Related Experiment Video
Updated: Mar 22, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Metabolic syndrome in prostate cancer: impact on risk and outcomes
Fatima H Karzai1, Ravi A Madan1, William L Dahut1
1Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Abstract:
Androgen-deprivation therapy (ADT) is a fundamental element of treatment for nonlocalized prostate cancer and for patients with high-risk disease who are not candidates for radical treatment. ADT has been linked to metabolic syndrome, which involves changes in metabolic factors. While distinct from classic metabolic syndrome, this type does include changes in body composition, lipid profiles and insulin resistance. The constellation of risk factors may be associated with cardiovascular morbidity and the onset of diabetes mellitus. Physicians should discuss in detail the risk and benefits of ADT, as well as any needed lifestyle modifications with patients before beginning therapy.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Psychoneuroimmunology: Diabetes and Cancer
Cancer Survival Analysis
Coronary Artery Disease I: Introduction

